Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Mini-HEART

Financiado

Cerrado

Human mini hearts looking for culprits and victims in cardiac disease

Cardiac disease causes morbidity and mortality as frequently as cancer. Predicting cardiac arrhythmia and cardiac failure, understanding multicellular (patho)physiological mechanisms, and devising new treatments represent unmet ne... ver más

31/08/2026

UNIPD

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

UNIVERSITA DEGLI STUDI DI PADOVA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-07-23

ERC-2020-COG: ERC CONSOLIDATOR GRANTS

I+D

Cerrada hace 4 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

UNIPD

1.50M€ | Lider

BATZ S COOP

603.18K€ | Participante

Leiden University Medical Ce...

500.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

STOP-HF STEM CELL MODELS TO UNRAVEL THE SUSCEPTIBILITY AND RESILIENC... 1M€ Cerrado

TECHNOBEAT Tools and TECHNOlogies for Breakthrough in hEArt Therapies 6M€ Cerrado

CAMEOS Cardiac micro engineered tissue for high throughput screenin... 261K€ Cerrado

BIOCARD Deep BIOmodeling of human CARDiogenesis 2M€ Cerrado

INDIVUHEART Individualized early risk assessment for heart diseases 2M€ Cerrado

SiGNATURE Selection of human iPSC derived cardiomyocytes by sinGle cel... 188K€ Cerrado

Duración del proyecto: 61 meses Fecha Inicio: 2021-07-23
Fecha Fin: 2026-08-31

Líder del proyecto

UNIVERSITA DEGLI STUDI DI PADOVA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cardiac disease causes morbidity and mortality as frequently as cancer. Predicting cardiac arrhythmia and cardiac failure, understanding multicellular (patho)physiological mechanisms, and devising new treatments represent unmet needs in the field. Human induced pluripotent stem cells (hiPSC) could revolutionise the way we study human disease but unfortunately, they still fall short in recapitulating variable phenotypes and complex cardiovascular diseases. This is partly due to functional immaturity of hiPSC-derived cardiac tissues, shortage of methods for accurate functional analysis and inability to identify cell-type specific contributions to disease pathology. I will address these challenges in Mini-HEART. We recently assembled novel three-dimensional multi-cellular cardiac microtissues as an important step towards full maturation and used these to demonstrate that cardiac disease mutations might directly affect non-myocyte cardiac cells. However, application of hiPSC microtissues to precision medicine remains to emerge. Using a multidisciplinary approach, I will combine isogenic hiPSC, their differentiation into distinct cell types of the heart, multifaceted biophysical assays, and tissue engineering to prove cell-type causality of disease and identify new molecules targeting the culprit cells to rescue the disease phenotype. I plan to use our unique complex hiPSC-cardiac microtissue to 1) identify and synthetically enhance maturation mechanisms; 2) reveal late arrhythmic and fibrotic phenotypes; 3) dissect cell-type specific contributions to complex cardiac diseases, including the role of macrophages and sympathetic nerves; 4) test two therapeutic strategies based on drug-tailoring and gene editing, to modulate the disease phenotype. Together, Mini-HEART will create new opportunities for designing novel biomedical tools to i) capture phenotypic changes, ii) reveal (patho)physiological mechanisms and ii) develop new therapeutic approaches for heart disease.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores